Skip to content

⌘K

Screener Chart SD50 Calendar News

Home Chart Calendar News

Scribe Therapeutics Inc. (SCTX) Stock | LOPJLB

Scribe Therapeutics Inc. (SCTX)

Healthcare · Biotechnology · NASDAQ · US

$15.41-14.20%Close

SCTX

$15.41-14.20%

Overview Financials Earnings Analyst & RatingsAnalyst News Holders & ETFsHolders Options

Snapshot

Price & returns

1 week: -23.3%-22.8% vs SPY
1 month: -41.9%-40.9% vs SPY

Valuation

Market cap: $249.4M

Short interest & options

Days to cover: 3.6
Short change: +212.1%

Street & earnings

Consensus: Buy1 buy · 0 hold · 0 sell
Price target: $51.75+235.8% upside

Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year

Price & returns: 3 years, 5 years

Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)

Signal evidence

Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)

Related

Lists

Quality dividend stocks

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

About

Scribe Therapeutics Inc. (SCTX). Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

SEC filingsCIK 1853921

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

CountryUS

CEOBenjamin L. Oakes

IPOJul 24

Employees82

Shares outstanding16.2M

Float-

Free float-

Websitescribetx.com ↗

Key executives

Benjamin L. OakesCo-Founder, President, CEO & ChairmanUSD 575K
David L. ParrotCFO & TreasurerUSD 476K
Svetlana LucasChief Business OfficerUSD 467K
Jennifer A. DoudnaCo-Founder & Scientific Advisor
David F. SavageCo-Founder & Scientific Advisor
Brett T. StaahlCo-Founder & VP of External Innovation

Snapshot

Price & returns1 month -41.9%

1 week: -23.3%-22.8% vs SPY
1 month: -41.9%-40.9% vs SPY

Open the chart →

Valuationmarket cap $249.4M

Market cap: $249.4M

Open Financials →

Short interest & optionsDays to cover 3.6 · Short change +212.1%

Days to cover: 3.6
Short change: +212.1%

Open Options →

Street & earningsTarget $51.75 (+235.8% upside)1 buy · 0 hold · 0 sell

Consensus: Buy1 buy · 0 hold · 0 sell
Price target: $51.75+235.8% upside

Open Analyst →

Signal evidence

Related

Lists

Quality dividend stocks

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

About

Scribe Therapeutics Inc. (SCTX). Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

SEC filingsCIK 1853921

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

CountryUS

CEOBenjamin L. Oakes

IPOJul 24

Employees82

Shares outstanding16.2M

Float-

Free float-

Websitescribetx.com ↗

Key executives

Benjamin L. OakesCo-Founder, President, CEO & ChairmanUSD 575K
David L. ParrotCFO & TreasurerUSD 476K
Svetlana LucasChief Business OfficerUSD 467K
Jennifer A. DoudnaCo-Founder & Scientific Advisor

Earnings history

LOADING…

Loading earnings…

Earnings history

Loading…

Loading earnings…

Company news

fool.com · 6d ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

seekingalpha.com · 11d ago

Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst

defenseworld.net · 28d ago

Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts

globenewswire.com · 54d ago

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

globenewswire.com · 55d ago

Scribe Therapeutics to Participate in Upcoming Investor Conferences

247wallst.com · 56d ago

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

globenewswire.com · 91d ago

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Market news & ticker search · RSS for SCTX

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Docs Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener Best dividend stocks Undervalued stocks Best S&P 500 stocks

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCP(Enterprise)·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

DATA 2026-10-23

LOPJLB.COM

OHLCOHLC, Essential layerEMAEMALEVELS, Essential layerSTOPStop, Essential layerFLIPFlip, Essential layer52W52-weekSIGNALS, Essential layerBUYBuy, Essential layerSELLSell, Essential layerEXHExhaustion, Essential layerEXH ZONEExhaustion zone, Essential layerCOILCoil

Oct 23, 2026O 17.88H 18.55L 15.12C 15.41-14.20%V 861.4K